scholarly journals Harnessing the Anti-Cancer Natural Product Nimbolide for Targeted Protein Degradation

2018 ◽  
Author(s):  
Jessica N. Spradlin ◽  
Xirui Hu ◽  
Carl C. Ward ◽  
Scott M. Brittain ◽  
Michael D. Jones ◽  
...  

AbstractNimbolide, a terpenoid natural product derived from the Neem tree, impairs cancer pathogenicity across many types of human cancers; however, the direct targets and mechanisms by which nimbolide exerts its effects are poorly understood. Here, we used activity-based protein profiling (ABPP) chemoproteomic platforms to discover that nimbolide reacts with a novel functional cysteine crucial for substrate recognition in the E3 ubiquitin ligase RNF114. Nimbolide impairs breast cancer cell proliferation in-part by disrupting RNF114 substrate recognition, leading to inhibition of ubiquitination and degradation of the tumor-suppressors such as p21, resulting in their rapid stabilization. We further demonstrate that nimbolide can be harnessed to recruit RNF114 as an E3 ligase in targeted protein degradation applications and show that synthetically simpler scaffolds are also capable of accessing this unique reactive site. Our study highlights the utility of ABPP platforms in uncovering unique druggable modalities accessed by natural products for cancer therapy and targeted protein degradation applications.

2019 ◽  
Vol 15 (7) ◽  
pp. 747-755 ◽  
Author(s):  
Jessica N. Spradlin ◽  
Xirui Hu ◽  
Carl C. Ward ◽  
Scott M. Brittain ◽  
Michael D. Jones ◽  
...  

Author(s):  
Mai Luo ◽  
Jessica N. Spradlin ◽  
Scott M. Brittain ◽  
Jeffery M. McKenna ◽  
John A. Tallarico ◽  
...  

AbstractThe translation of natural product function to fully synthetic small molecules has remained an important process in medicinal chemistry for decades resulting in numerous FDA-approved medicines. We recently discovered that the terpene natural product nimbolide can be utilized as a covalent recruiter of the E3 ubiquitin ligase RNF114 for use in targeted protein degradation (TPD) – a powerful therapeutic modality within modern day drug discovery. Using activity-based protein profiling-enabled covalent ligand screening approaches, we herein report the discovery of fully synthetic RNF114-based recruiter molecules that can also be exploited for PROTAC applications, and demonstrate their utility in degrading therapeutically relevant targets such as BRD4 and BCR-ABL in cells. The identification of simple and easily manipulated drug-like scaffolds that can mimic the function of a complex natural product is beneficial in further expanding the toolbox of E3 ligase recruiters, an area of great importance in drug discovery and chemical biology.


2019 ◽  
Vol 18 (7) ◽  
pp. 459-474 ◽  
Author(s):  
Paramita Ghosh ◽  
Debarpan Mitra ◽  
Sreyashi Mitra ◽  
Sudipta Ray ◽  
Samir Banerjee ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document